ArticleJournal of immunology (Baltimore, Md. : 1950)2019
ZBP1/DAI Drives RIPK3-Mediated Cell Death Induced by IFNs in the Absence of RIPK1.
Open access · greenAbstract read
In one paragraph
Article in Journal of immunology (Baltimore, Md. : 1950), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 102 citations in OpenAlex.
- Biological consequences of Z-nucleic acid sensing by ZBP1 and ADAR1.RNA biology · 2026Review
- Mechanisms, regulation and clinical relevance of necroptosis.Nature reviews. Molecular cell biology · 2026Review
- ZBP1-mediated Treg cell dysfunction exacerbates neuroimmune dysregulation in Alzheimer's disease under metabolic stress.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Interaction between p-AMPK and RIPK3 reveals a mechanism by which AdipoAI suppresses necroptosis to attenuate periodontitis.Journal of translational medicine · 2026Article
- PANoptosis in the pathogenesis of myelodysplastic syndromes.Molecular oncology · 2026Review
- Programmed cell death in cancer: targeting necroptosis to kill tumor cell.Cell death discovery · 2026Review
- Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Spatial transcriptomic analysis identifies a necroptosis-prone thyroid follicular cell state in Hashimoto's thyroiditis.Frontiers in immunology · 2026Article
- ZBP1 as a dynamic monitor of viral replication: implications for therapeutic strategies.Frontiers in cellular and infection microbiology · 2026Review
- Article
- Spliceosome inhibition induces Z-RNA and ZBP1-driven cell death in small cell lung cancer.Cell reports · 2025Article
- Stress granule-mediated ZBP1 activation drives necroptotic cell death in non-obstructive azoospermia and testicular aging.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Programmed Cell Death in Heart Failure: Mechanisms, Impacts, and Therapeutic Prospects.Reviews in cardiovascular medicine · 2025Review
- Necroptosis in myocardial ischaemia-reperfusion injury: current update on mechanisms, therapeutic targets, and translational potential.Apoptosis : an international journal on programmed cell death · 2025Review
- Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy.Nature communications · 2025Article
- Zα and Zβ Localize ADAR1 to Flipons That Modulate Innate Immunity, Alternative Splicing, and Nonsynonymous RNA Editing.International journal of molecular sciences · 2025Review
- Innate Immune Sensors and Cell Death-Frontiers Coordinating Homeostasis, Immunity, and Inflammation in Skin.Viruses · 2025Review
- Necroptosis in obesity: a complex cell death event.Apoptosis : an international journal on programmed cell death · 2025Review
- RIPK1 signaling pathways: implications for autoimmune and neuroinflammatory diseases.Frontiers in immunology · 2025Review
- Role of necroptosis in pulpitis: integration of bacterial infection, immune imbalance, and oxidative stress.PeerJ · 2025Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Justin P IngramBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111.
Roshan J ThapaBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111.ORCID 0000-0002-1852-0616
Amanda FisherDepartment of Microbiology, Immunology & Molecular Genetics, UT Health Science Center at San Antonio, San Antonio, TX 78229; and.ORCID 0000-0002-2634-144X
Bart TummersDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105.
Ting ZhangBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111.
Chaoran YinBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111.
Diego A RodriguezDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105.ORCID 0000-0003-4771-0221
Hongyan GuoDepartment of Microbiology, Immunology & Molecular Genetics, UT Health Science Center at San Antonio, San Antonio, TX 78229; and.
Rebecca LaneDepartment of Microbiology, Immunology & Molecular Genetics, UT Health Science Center at San Antonio, San Antonio, TX 78229; and.
Riley WilliamsBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111.
Michael J SlifkerBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111.ORCID 0000-0002-9718-5966
Suresh H BasagoudanavarBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111.ORCID 0000-0001-7714-3120
Glenn F RallBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111.
Christopher P DillonDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105.
Douglas R GreenDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105.
William J KaiserDepartment of Microbiology, Immunology & Molecular Genetics, UT Health Science Center at San Antonio, San Antonio, TX 78229; and kaiserw@uthscsa.edu Siddharth.balachandran@fccc.edu.
Siddharth BalachandranBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111; kaiserw@uthscsa.edu Siddharth.balachandran@fccc.edu.
Fox Chase Cancer Center · USSt. Jude Children's Research Hospital · USThe University of Texas Health Science Center at San Antonio · US
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MWORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8MMECHANISMS OF REGULATED CELL DEATHR35CA231620 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Douglas R. Green · 2018 to 2026
$9.2MMechanism, Function, and Exploitation of Influenza A Virus-Activated Cell DeathR01AI135025 · NIAID · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH · 2017 to 2025
$6.8MSurvival Function of the Fadd-Caspase-8-Flip ComplexR01AI044828 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GREEN, DOUGLAS R. · 1999 to 2016
$6.3MSurvival Function of the Fadd-Caspase-8-Flip Complex - MERIT ExtensionR37AI044828 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Douglas R. Green · 2017 to 2026
$4.5MRIP1/3 Kinases as New Targets in Malignant MesotheliomaR01CA190542 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH, TESTA, JOSEPH R. · 2015 to 2019
$2.1MRIP1 and RIP3 regulation of apoptosis, necrosis, and inflammationDP5OD012198 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KAISER, WILLIAM JOSEPH · 2012 to 2016
$1.9MInterferon Activated Necroptosis as a New Therapeutic Avenue for Kidney CancerR01CA168621 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH · 2014 to 2018
$1.9MTargeting RIPK3 in Age-Related Inflammation and InjuryR56AG058642 · NIA · TUFTS UNIVERSITY BOSTON · PI BALACHANDRAN, SIDDHARTH, CUNY, GREGORY D · 2018 to 2018
$649kNCI NIH HHS P30 CA006927NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA168621NCI NIH HHS R01 CA190542NCI NIH HHS R35 CA231620NIAID NIH HHS R01 AI044828NIAID NIH HHS R01 AI135025NIAID NIH HHS R37 AI044828NIA NIH HHS R56 AG058642NIH HHS DP5 OD012198
Abstract
Receptor-interacting protein kinase 1 (RIPK1) regulates cell fate and proinflammatory signaling downstream of multiple innate immune pathways, including those initiated by TNF-α, TLR ligands, and IFNs. Genetic ablation of
Indexed as
AnimalsApoptosisCaspase 8Cell DeathCell LineInflammationMiceMice, Inbred C57BLReceptor-Interacting Protein Serine-Threonine KinasesRNA-Binding ProteinsSignal TransductionTumor Necrosis Factor-alphaCaspase 8Receptor-Interacting Protein Serine-Threonine KinasesRipk1 protein, mouseRipk3 protein, mouseRNA-Binding ProteinsTumor Necrosis Factor-alphaZbp1 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.